Literature DB >> 31988689

Electrophysiologic Complications in Cancer Patients.

Dae Hyun Lee1, Sanjay Chandrashekhar1, Michael G Fradley1,2.   

Abstract

In recent years, dramatic advances in both cancer diagnosis and treatment have led to significantly increased survival rates. As such, cardiovascular toxicities due to oncologic treatments are more frequently identified. Although heart failure and cardiomyopathy have historically been the cardiotoxicities most associated with cancer therapeutics, it is now recognized that all components of the cardiovascular system can be affected. In this review, we discuss electrophysiologic complications of cancer treatments, including atrial and ventricular tachyarrhythmias as well as bradyarrhythmias, and recommend a multidisciplinary approach with both cardiologists and oncologists to provide safe and effective care to these patients.
© 2019 Houston Methodist Hospital Houston, Texas.

Entities:  

Keywords:  atrial arrhythmias; bradyarrhythmias; cardio-oncology; cardiotoxicity; ventricular arrhythmias

Mesh：

Substances：

Year:  2019        PMID： 31988689      PMCID： PMC6977558          DOI： 10.14797/mdcj-15-4-282

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN： 1947-6108


  47 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy.

Authors:  Michela Brambatti; Rebecca Mathew; Barbara Strang; Joan Dean; Anuja Goyal; Joseph E Hayward; Laurene Long; Patty DeMeis; Marcia Smoke; Stuart J Connolly; Carlos A Morillo; Guy Amit; Alessandro Capucci; Jeff S Healey
Journal:  Heart Rhythm       Date:  2015-06-03       Impact factor: 6.343

Review 3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

4.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

5.  A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.

Authors:  Lambros Zellos; William G Richards; Leah Capalbo; Michael T Jaklitsch; Lucian R Chirieac; Bruce E Johnson; Raphael Bueno; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 5.209

6.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

7.  Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.

Authors:  Anthony R Mato; Suparna Clasen; Peter Pickens; Lisa Gashonia; Joanna Rhodes; Jakub Svoboda; Mitchell Hughes; Chadi Nabhan; Naveed Ali; Stephen Schuster; Joseph Carver
Journal:  Cancer Biol Ther       Date:  2017-12-27       Impact factor: 4.742

8.  Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Authors:  Lucie Heinzerling; Patrick A Ott; F Stephen Hodi; Aliya N Husain; Azadeh Tajmir-Riahi; Hussein Tawbi; Matthias Pauschinger; Thomas F Gajewski; Evan J Lipson; Jason J Luke
Journal:  J Immunother Cancer       Date:  2016-08-16       Impact factor: 13.751

9.  Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity.

Authors:  Zhushan Zhang; Tai-Qin Huang; Igor Nepliouev; Hengtao Zhang; Adam S Barnett; Paul B Rosenberg; Sai-Hong I Ou; Jonathan A Stiber
Journal:  Cardiooncology       Date:  2017-01-19

10.  Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.

Authors:  Surbhi Shah; Faye L Norby; Yvonne H Datta; Pamela L Lutsey; Richard F MacLehose; Lin Y Chen; Alvaro Alonso
Journal:  Blood Adv       Date:  2018-02-13
View more
  1 in total

Review 1.  Palpitations in the Cancer Patient.

Authors:  Hani Essa; Gregory Yh Lip
Journal:  Eur Cardiol       Date:  2021-12-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.